NO324719B1 - Anvendelse av 8-nitro-2,3,4,5-tetrahydro-1H-3-benzazepiner for fremstilling av en farmasoytisk sammensetning for behandling av soveuregelmessigheter - Google Patents

Anvendelse av 8-nitro-2,3,4,5-tetrahydro-1H-3-benzazepiner for fremstilling av en farmasoytisk sammensetning for behandling av soveuregelmessigheter Download PDF

Info

Publication number: NO324719B1
Authority: NO; Norway
Prior art keywords: sleep; treatment; tetrahydro; compound; acid
Prior art date: 1997-03-12

Application number

NO19994343A

Other languages

English (en)

Norwegian (no)

Other versions

NO994343L (no

NO994343D0 (no

Inventor

Christian Foged

Anders Fink-Jensen

Original Assignee

Addex Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-12

Filing date

1999-09-07

Publication date

2007-12-03

1999-09-07 Application filed by Addex Pharma Sa filed Critical Addex Pharma Sa

1999-09-07 Publication of NO994343D0 publication Critical patent/NO994343D0/no

1999-11-11 Publication of NO994343L publication Critical patent/NO994343L/no

2007-12-03 Publication of NO324719B1 publication Critical patent/NO324719B1/no

Links

208000019116 sleep disease Diseases 0.000 title claims abstract description 21
238000011282 treatment Methods 0.000 title claims abstract description 13
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
238000002360 preparation method Methods 0.000 title claims description 3
TXJXCXSFIVCGDS-UHFFFAOYSA-N 34583-83-0 Chemical class C1CNCCC2=CC([N+](=O)[O-])=CC=C21 TXJXCXSFIVCGDS-UHFFFAOYSA-N 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 39
150000003839 salts Chemical class 0.000 claims abstract description 17
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 5
206010022437 insomnia Diseases 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 5
239000000203 mixture Substances 0.000 claims description 4
XZPSYCOYKJRHKE-UHFFFAOYSA-N 5-(2,3-dihydro-1-benzofuran-7-yl)-3-methyl-8-nitro-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound C1N(C)CCC2=CC([N+]([O-])=O)=C(O)C=C2C1C1=CC=CC2=C1OCC2 XZPSYCOYKJRHKE-UHFFFAOYSA-N 0.000 claims description 3
208000020685 sleep-wake disease Diseases 0.000 claims description 2
208000022925 sleep disturbance Diseases 0.000 abstract description 9
229910052739 hydrogen Inorganic materials 0.000 abstract description 5
239000001257 hydrogen Substances 0.000 abstract description 5
239000003937 drug carrier Substances 0.000 abstract description 2
125000000217 alkyl group Chemical group 0.000 abstract 3
150000002431 hydrogen Chemical group 0.000 abstract 3
229910052736 halogen Inorganic materials 0.000 abstract 2
150000002367 halogens Chemical class 0.000 abstract 2
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
230000007958 sleep Effects 0.000 description 12
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
XWEWSCUVTBLEBS-PKLMIRHRSA-N acetic acid;(5s)-8-chloro-5-(2,3-dihydro-1-benzofuran-7-yl)-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound CC(O)=O.C1N(C)CCC2=CC(Cl)=C(O)C=C2[C@H]1C1=CC=CC2=C1OCC2 XWEWSCUVTBLEBS-PKLMIRHRSA-N 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
210000002966 serum Anatomy 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000001647 drug administration Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000000034 method Methods 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
IYEONNAQPKSZJI-UHFFFAOYSA-N 5-(2,3-dihydro-1-benzofuran-7-yl)-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound C1N(C)CCC2=CC=C(O)C=C2C1C1=CC=CC2=C1OCC2 IYEONNAQPKSZJI-UHFFFAOYSA-N 0.000 description 2
SKMVRXPBCSTNKE-UHFFFAOYSA-N 8-chloro-5-(2,3-dihydro-1-benzofuran-7-yl)-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound C1N(C)CCC2=CC(Cl)=C(O)C=C2C1C1=CC=CC2=C1OCC2 SKMVRXPBCSTNKE-UHFFFAOYSA-N 0.000 description 2
229940123100 Dopamine D1 receptor antagonist Drugs 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
235000011054 acetic acid Nutrition 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
230000000561 anti-psychotic effect Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000013078 crystal Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
229960003638 dopamine Drugs 0.000 description 2
239000003210 dopamine receptor blocking agent Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000012065 filter cake Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000036385 rapid eye movement (rem) sleep Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
JUDKOGFHZYMDMF-UHFFFAOYSA-N 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol Chemical compound C1=2C=C(O)C(O)=CC=2CCNCC1C1=CC=CC=C1 JUDKOGFHZYMDMF-UHFFFAOYSA-N 0.000 description 1
MHMRQHMKGYLQKH-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-3-benzazepin-7-ol Chemical class C1CNCCC2=CC(O)=CC=C21 MHMRQHMKGYLQKH-UHFFFAOYSA-N 0.000 description 1
MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
RUSANBIFMAXXSJ-UHFFFAOYSA-N 5-(1-benzofuran-7-yl)-8-chloro-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound C1N(C)CCC2=CC(Cl)=C(O)C=C2C1C1=CC=CC2=C1OC=C2 RUSANBIFMAXXSJ-UHFFFAOYSA-N 0.000 description 1
ZJIUEDYXZUIMNV-UHFFFAOYSA-N 7-chloro-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical class C1CNCCC2=CC(Cl)=CC=C21 ZJIUEDYXZUIMNV-UHFFFAOYSA-N 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
101150049660 DRD2 gene Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
108090000511 Dopamine D1 Receptors Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
-1 NNC 0756 Chemical class 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Chemical class 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
229940005529 antipsychotics Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
208000028683 bipolar I disease Diseases 0.000 description 1
239000000872 buffer Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
230000009699 differential effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000000433 dopamine 1 receptor blocking agent Substances 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
229910052500 inorganic mineral Chemical class 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
239000011707 mineral Chemical class 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000008452 non REM sleep Effects 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
238000000746 purification Methods 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000006665 regulation of circadian sleep/wake cycle, REM sleep Effects 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000004622 sleep time Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
230000024664 tolerance induction Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO19994343A 1997-03-12 1999-09-07 Anvendelse av 8-nitro-2,3,4,5-tetrahydro-1H-3-benzazepiner for fremstilling av en farmasoytisk sammensetning for behandling av soveuregelmessigheter NO324719B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DK26597		1997-03-12
US4150997P	1997-03-24	1997-03-24
PCT/DK1998/000088 WO1998040072A1 (fr)	1997-03-12	1998-03-11	Utilisation de 2,3,4,5-tetrahydro-1h-3-benzazepines pour la fabrication d'une composition pharmaceutique pour le traitement des troubles du sommeil

Publications (3)

Publication Number	Publication Date
NO994343D0 NO994343D0 (no)	1999-09-07
NO994343L NO994343L (no)	1999-11-11
NO324719B1 true NO324719B1 (no)	2007-12-03

Family

ID=26063641

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19994343A NO324719B1 (no)	1997-03-12	1999-09-07	Anvendelse av 8-nitro-2,3,4,5-tetrahydro-1H-3-benzazepiner for fremstilling av en farmasoytisk sammensetning for behandling av soveuregelmessigheter

Country Status (16)

Country	Link
US (1)	US6211173B1 (fr)
EP (1)	EP1011679B1 (fr)
JP (1)	JP2001515484A (fr)
AT (1)	ATE245986T1 (fr)
AU (1)	AU742873B2 (fr)
BR (1)	BR9808234A (fr)
CA (1)	CA2283083C (fr)
CZ (1)	CZ296464B6 (fr)
DE (1)	DE69816832T2 (fr)
DK (1)	DK1011679T3 (fr)
ES (1)	ES2203933T3 (fr)
IL (1)	IL131670A (fr)
NO (1)	NO324719B1 (fr)
PL (1)	PL189822B1 (fr)
PT (1)	PT1011679E (fr)
WO (1)	WO1998040072A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005035504A2 (fr) *	2003-05-22	2005-04-21	Schering Corporation	Antagonistes selectifs des recepteurs d1/d5 utilises dans le traitement de l'obesite et des troubles du systeme nerveux central
PL1691811T3 (pl) *	2003-12-11	2014-12-31	Sunovion Pharmaceuticals Inc	Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
US20050215521A1 (en) *	2003-12-22	2005-09-29	Karim Lalji	Modafinil combination therapy for improving sleep quality
EP1696959A2 (fr) *	2003-12-24	2006-09-06	Sepracor, Inc.	Polytherapie a base de melatonine destinee a ameliorer la qualite du sommeil
DK1742624T3 (da) *	2004-02-18	2010-03-08	Sepracor Inc	Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK325188D0 (da) *	1988-06-15	1988-06-15	Novo Industri As	Hidtil ukendte benzazepinderivater
US5470850A (en) *	1992-02-24	1995-11-28	Novo Nordisk A/S	2,3,4,5-tetrahydro-1H-3-benzazepines
DK26793D0 (da) *	1993-03-10	1993-03-10	Novo Nordisk As	Benzofuranyl- eller dihydrobenzofuranyl-substituerede tricycliske benzazepiner, der anvendelse og fremstilling

1998
- 1998-03-11 EP EP98907896A patent/EP1011679B1/fr not_active Expired - Lifetime
- 1998-03-11 PL PL98335545A patent/PL189822B1/pl not_active IP Right Cessation
- 1998-03-11 DK DK98907896T patent/DK1011679T3/da active
- 1998-03-11 US US09/380,840 patent/US6211173B1/en not_active Expired - Fee Related
- 1998-03-11 IL IL13167098A patent/IL131670A/xx not_active IP Right Cessation
- 1998-03-11 PT PT98907896T patent/PT1011679E/pt unknown
- 1998-03-11 WO PCT/DK1998/000088 patent/WO1998040072A1/fr not_active Ceased
- 1998-03-11 CZ CZ0317799A patent/CZ296464B6/cs not_active IP Right Cessation
- 1998-03-11 AT AT98907896T patent/ATE245986T1/de active
- 1998-03-11 AU AU66100/98A patent/AU742873B2/en not_active Ceased
- 1998-03-11 DE DE69816832T patent/DE69816832T2/de not_active Expired - Lifetime
- 1998-03-11 ES ES98907896T patent/ES2203933T3/es not_active Expired - Lifetime
- 1998-03-11 JP JP53910298A patent/JP2001515484A/ja not_active Ceased
- 1998-03-11 BR BR9808234-5A patent/BR9808234A/pt not_active Application Discontinuation
- 1998-03-11 CA CA002283083A patent/CA2283083C/fr not_active Expired - Fee Related
1999
- 1999-09-07 NO NO19994343A patent/NO324719B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CZ296464B6 (cs)	2006-03-15
AU742873B2 (en)	2002-01-17
US6211173B1 (en)	2001-04-03
JP2001515484A (ja)	2001-09-18
CZ317799A3 (cs)	2000-03-15
ES2203933T3 (es)	2004-04-16
CA2283083A1 (fr)	1998-09-17
PT1011679E (pt)	2003-12-31
AU6610098A (en)	1998-09-29
NO994343L (no)	1999-11-11
PL189822B1 (pl)	2005-09-30
IL131670A (en)	2005-07-25
DE69816832D1 (de)	2003-09-04
BR9808234A (pt)	2000-05-16
WO1998040072A1 (fr)	1998-09-17
EP1011679A1 (fr)	2000-06-28
EP1011679B1 (fr)	2003-07-30
DK1011679T3 (da)	2003-11-24
NO994343D0 (no)	1999-09-07
IL131670A0 (en)	2001-01-28
PL335545A1 (en)	2000-04-25
CA2283083C (fr)	2007-09-04
ATE245986T1 (de)	2003-08-15
DE69816832T2 (de)	2004-05-27

Legal Events

Date	Code	Title	Description
2012-10-22	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US12083090B2 (en)	2024-09-10	Methods of using low-dose doxepin for the improvement of sleep
KR101536023B1 (ko)	2015-07-10	조합된 ｓｅｒｔ, ５－ｈｔ３ 및 ５－ｈｔ１ａ 활성을 가진 화합물의 치료 용도
US20090042971A1 (en)	2009-02-12	Method of using low-dose doxepin for the improvement of sleep
US20090042972A1 (en)	2009-02-12	Methods of using low-dose doxepin for the improvement of sleep
JPH085787B2 (ja)	1996-01-24	痴呆及び脳血管障害予防・治療剤並びに血小板凝集抑制剤
TWI859303B (zh)	2024-10-21	受體作動活性的化合物的鹽及結晶形
US3326896A (en)	1967-06-20	Embonic acid addition salts of 10, 11-dihydro-5h-dibenz[b, f]azepines
NO324719B1 (no)	2007-12-03	Anvendelse av 8-nitro-2,3,4,5-tetrahydro-1H-3-benzazepiner for fremstilling av en farmasoytisk sammensetning for behandling av soveuregelmessigheter
US7338955B1 (en)	2008-03-04	Medicament for treatment of neuropathies
CZ300429B6 (cs)	2009-05-20	Lécivo ke zmírnení deprese nebo úzkostných stavu
KR20040039446A (ko)	2004-05-10	치환된 알킬아미노피리다지논 유도체, 이의 제조 방법 및이를 함유하는 약제학적 조성물
HUP0000679A2 (hu)	2000-09-28	2,3,4,5-Tetrahidro-1H-benzazepinek alkalmazása alvási rendellenesség ellen ható gyógyászati készítmény előállítására
MXPA99008341A (en)	2000-08-01	Use of 2,3,4,5-tetrahydro-1h-3-benzazepines for the manufacture of a pharmaceutical composition for the treatment of sleep disorders
US3639609A (en)	1972-02-01	Drug of adreno-blocking action
KR950009092B1 (ko)	1995-08-14	뇌세포 보호 작용을 가지는 의약 조성물
WO2003087091A1 (fr)	2003-10-23	Nouveau cristal d'anhydride de derive de quinoxalinedione
EP0407016A2 (fr)	1991-01-09	Utilisation de dérivés du benzodioxinopyrrole pour l'obtention d'um médicament destiné au traitement de l'anxiété
WO1993004685A1 (fr)	1993-03-18	Imides polycycliques antidepressifs
JPS63183532A (ja)	1988-07-28	脳障害改善剤